Novan, Inc. (NASDAQ:NOVN – Get Rating) – Research analysts at Cantor Fitzgerald boosted their FY2023 earnings per share estimates for Novan in a report issued on Wednesday, November 16th. Cantor Fitzgerald analyst J. Kim now anticipates that the company will post earnings per share of ($0.98) for the year, up from their prior estimate of ($1.41). The consensus estimate for Novan’s current full-year earnings is ($1.71) per share.
A number of other research firms have also recently commented on NOVN. HC Wainwright reduced their price target on Novan from $24.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, August 16th. StockNews.com assumed coverage on Novan in a report on Wednesday, October 12th. They set a “sell” rating for the company.
Novan Stock Performance
Institutional Investors Weigh In On Novan
A number of institutional investors have recently made changes to their positions in the company. Armistice Capital LLC boosted its holdings in shares of Novan by 75.4% during the third quarter. Armistice Capital LLC now owns 2,293,000 shares of the company’s stock worth $4,288,000 after acquiring an additional 985,897 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Novan by 1.1% during the first quarter. Vanguard Group Inc. now owns 789,719 shares of the company’s stock worth $3,112,000 after acquiring an additional 8,899 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Novan by 11.1% during the first quarter. Renaissance Technologies LLC now owns 382,665 shares of the company’s stock worth $1,508,000 after acquiring an additional 38,293 shares during the period. Wealthsource Partners LLC bought a new stake in shares of Novan during the third quarter worth approximately $291,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Novan during the first quarter worth approximately $501,000. Institutional investors own 15.65% of the company’s stock.
Novan Company Profile
Novan, Inc, a medical dermatology company, focuses on researching, developing, and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases.
- Get a free copy of the StockNews.com research report on Novan (NOVN)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Novan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan and related companies with MarketBeat.com's FREE daily email newsletter.